Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Equity Average (2024 - 2025)

Prelude Therapeutics' Equity Average history spans 2 years, with the latest figure at $63.6 million for Q4 2025.

  • For Q4 2025, Equity Average fell 55.83% year-over-year to $63.6 million; the TTM value through Dec 2025 reached $63.6 million, down 55.83%, while the annual FY2025 figure was $100.0 million, N/A changed from the prior year.
  • Equity Average for Q4 2025 was $63.6 million at Prelude Therapeutics, down from $67.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $196.5 million in Q2 2024 and bottomed at $63.6 million in Q4 2025.